Date: Sunday, November 8, 2020
Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA) is impacted by patients’ baseline MRI and C-reactive protein (CRP) status.
Methods: C-axSpAnd (NCT02552212) is a 3-year, phase 3, multicenter study including a completed 52‑week double-blind, placebo-controlled period.1 Patients were adults with a diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS), but not modified New York, classification criteria, active disease (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] >4, spinal pain >4), objective signs of inflammation (C‑reactive protein [CRP] >10 mg/mL [CRP+] and/or evidence of sacroiliitis on MRI [MRI+]), who had failed ≥2 non-steroidal anti-inflammatory drugs (NSAIDs). Patients were randomized 1:1 to placebo or CZP (400 mg at Weeks 0, 2 and 4, then 200 mg every 2 weeks), which they received in addition to non-biologic background medication for 52 weeks. Adjustments to background medication or switching to open-label CZP (or other biologics) at any point was permitted. We report Ankylosing Spondylitis Disease Activity Score – major improvement (ASDAS-MI) and ASAS 40% response (ASAS40) for CZP-randomized patients according to prespecified subgroups based on MRI/CRP status (MRI+/CRP+, MRI−/CRP+, MRI+/CRP−). Comparisons between MRI/CRP subgroups are descriptive only; Week 12 (ASAS40) and Week 52 (ASDAS-MI) comparisons between CZP and placebo were pre-specified. Missing values, or values collected after switching to open-label treatment, were imputed using non-responder imputation.
Results: At baseline, a total of 317 patients were randomized, 159 to CZP (45 MRI+/CRP+, 40 MRI−/CRP+ and 74 MRI+/CRP−) and 158 to placebo (42 MRI+/CRP+, 40 MRI−/CRP+ and 76 MRI+/CRP−). At Week 52, ASDAS-MI was achieved in 47.2% and 7.0% of CZP and placebo-treated patients, respectively, and ASAS40 in 56.6% and 15.8%. When stratified by MRI/CRP status, response rates in all three subgroups for CZP-treated patients were also higher compared to placebo for both ASDAS-MI and ASAS40 at Week 12 and Week 52 (Figure 1). For ASDAS-MI, there was a greater difference in response rates between subgroups compared with ASAS40, with numerically higher response rates in the MRI+/CRP+ and MRI−/CRP+ subgroups vs the MRI+/CRP− subgroup (Figure 1a). Since the ASDAS value is largely dependent on the CRP value, this is to be expected. For ASAS40, the main secondary outcome, a numerically higher response rate was also observed for the MRI+/CRP+ group, while response rates were comparable for the other groups (Figure 1b).
Conclusion: Clinically relevant responses were observed in nr-axSpA patients with either MRI and/or CRP positivity, with the highest response seen in the MRI+/CRP+ subgroup.
Reference: 1. Deodhar A. Arthritis Rheumatol 2019;71:1101–11.
To cite this abstract in AMA style:Deodhar A, Gensler L, Hall S, Robinson P, Hoepken B, Bauer L, Kumke T, Maksymowych W. Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/certolizumab-pegol-efficacy-in-patients-with-non-radiographic-axial-spondyloarthritis-stratified-by-baseline-mri-and-c-reactive-protein-status/. Accessed October 22, 2021.
« Back to ACR Convergence 2020
ACR Meeting Abstracts - https://acrabstracts.org/abstract/certolizumab-pegol-efficacy-in-patients-with-non-radiographic-axial-spondyloarthritis-stratified-by-baseline-mri-and-c-reactive-protein-status/